stockportfolio.pro
Stocks / PCVX vs SYRE
PCVX vs SYRE
Vaxcyte, Inc. and Spyre Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Vaxcyte, Inc. (PCVX) | Spyre Therapeutics, Inc. (SYRE) | |
|---|---|---|
| Market cap | $6.8B | $6.8B |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-766.63M | $-155.20M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | — |
| Return on equity | -28.5% | -21.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open PCVX — free Open SYRE — freeFrequently asked questions
Which is bigger, PCVX or SYRE?
Spyre Therapeutics, Inc. is larger by market capitalization — $6.8B versus $6.8B.
Which grows faster, PCVX or SYRE?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.